Navigation Links
Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
Date:3/28/2008

VANCOUVER, March 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that results from an investigator-sponsored Phase II study, in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), showed that a combination therapy of verteporfin (Visudyne(R)) followed by bevacizumab (Avastin(R)) reduced, by half, the number of treatments required during the first six months to gain similar visual acuity compared to Avastin monotherapy. In addition, 30% of the patients treated using the combination therapy required only a single combination treatment compared to Avastin monotherapy, with which all patients required additional treatments.

Visudyne therapy is approved for the treatment of age-related macular degeneration (AMD) in patients with predominantly classic subfoveal choroidal neovascularization. QLT Inc. is the manufacturer of Visudyne.

Dr. Michael Potter, the investigator-sponsor of the verteporfin and bevacizumab (VIA) clinical trial, which was supported by QLT, presented results today at the 31st Annual Macula Society Meeting that is being held this week in Florida. The objective of the VIA study was to determine whether Visudyne, at low or very low fluence rates, in combination with Avastin, reduces the average number of treatments required, compared to Avastin alone.

"We are very pleased with the clinical outcomes of this study. Our goal was to see if it is possible to minimize the number of treatments while maintaining or improving visual acuity in patients with CNV secondary to AMD. At six months, virtually all the patients treated with the Visudyne combination therapy gained visual acuity with half the number of treatments required with Avastin monotherapy. These results are encouraging, and more research continues to be done to evaluate the benefits of combination therapy in terms of helping patients improve their vision and also reducing the cost of t
'/>"/>

SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cystic Fibrosis Foundation announces positive early results for phase 2 clinical trial of VX-770
2. MRIs high false positive rate has little impact on womens choice of preventive mastectomy
3. AcroMetrix Announces Launch of First Liquid MRSA Positive Control
4. Make Your Mammogram a Positive Experience: Author Offers Guidelines and Tips to Change Womens Negative Attitudes Toward Mammograms
5. QLT announces positive FDA action on Aczone(TM)
6. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
7. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
8. Ibuprofen destroys aspirins positive effect on stroke risk
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Positive results from phase 1 clinical trials of cuprindro
11. Single reader with CAD more efficient, yields fewer false positives, and possibly more sensitive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... Teen substance abuse ranks as one of the most ... adolescents throughout North Carolina struggle with a drug or alcohol ... professional rehab due to a lack of information available to ... Teens Holly Springs is a helpline designed to make a ... abusers in Wake County who are seeking to overcome ...
(Date:8/22/2014)... August 23, 2014 2014 Deep ... a professional and in-depth research report on the ... Meter information, including Glucose Meter definition, classification, application, ... overview. This research covers the international market analysis, ... analysis covering macroeconomic environment & economic situation analysis. ...
(Date:8/22/2014)... August 22, 2014 AWeber, one ... that currently helps more than 120,000 small businesses ... the attention of Shane Michaels, prompting an investigative review. ... element for any online marketing campaign, despite what some ... the marketing world,” reports Michaels. “AWeber is a great ...
(Date:8/22/2014)... This report studies the "Sample Preparation Market by ... Kits (Isolation, Purification), By Application (Genomics, Proteomics), by ... 2018" This market was valued at $4,254.8 million ... a CAGR of 5.9% from 2013 to 2018, ... 98 market data Tables and 23 Figures spread ...
(Date:8/22/2014)... Millennium Treatment Group has recently noticed an ... level of drug use among teenagers. The treatment facility aims ... and work to minimize drug abuse. , America is currently ... addiction in history. According to the National Institute of ... aged 12 or older—or 9.2 percent of the population—had used ...
Breaking Medicine News(10 mins):Health News:New Helpline Provides Teen Drug & Alcohol Recovery Information in Holly Springs, NC 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2
... management solutions , today announced that Premier Inc. has selected ... , ... Jacksonville, FL (PRWEB) July ... compensation management solutions , today announced that Premier Inc. has ...
... years of education, completing specialized training and practicing medicine in fields ... College at Indiana University of Pennsylvania influence and enhance their chosen ... ... (PRWEB) July 16, 2008 -- Each day brings patients with different ...
... VendorClear™, the company who pioneered web-based vendor access services for ... and vendor representatives operate more efficiently and increase facility safety. ... ... July 16, 2008 -- VendorClear™, the company who pioneered web-based ...
... health professionals from across the country will convene July ... and policy issues faced by public health officials and ... , "Confronting the Ethics of Pandemic Influenza Planning: ... the Indiana State Department of Health, the Indiana University ...
... in America for Over 26,Million Americans Suffering from ... WASHINGTON, July 15 In response to today,s,passage ... Partners (KCP) -- an,alliance of patient advocates, dialysis ... quality of care for individuals,with kidney disease and ...
... Quality through National E-Prescribing, ... AARP ... DESKS: AARP,is recording House and Senate roll call votes on key issues ... results,of these key votes., , SUMMARY: Today the U.S. House of ...
Cached Medicine News:Health News:Premier Inc Automates their Compensation Management Processes, Chooses HCR Software's CompensationXL Product 2Health News:Premier Inc Automates their Compensation Management Processes, Chooses HCR Software's CompensationXL Product 3Health News:Premier Inc Automates their Compensation Management Processes, Chooses HCR Software's CompensationXL Product 4Health News:Robert E Cook Honors College Women In Medicine 2Health News:Robert E Cook Honors College Women In Medicine 3Health News:Robert E Cook Honors College Women In Medicine 4Health News:Robert E Cook Honors College Women In Medicine 5Health News:Robert E Cook Honors College Women In Medicine 6Health News:VendorClear™ Introduces Revolutionary Products for Healthcare Facilities and Vendor Representatives 2Health News:Confronting Ethics of Pandemic Influenza Planning: 2008 Summit of the States 2Health News:Kidney Community Thanks Congress for Passing Landmark End Stage Renal Disease (ESRD) Reform 2Health News:AARP Thanks Congress for Keeping Medicare Fair, Overriding White House Veto 2Health News:AARP Thanks Congress for Keeping Medicare Fair, Overriding White House Veto 3
(Date:8/22/2014)... , Aug. 22, 2014  WaferGen Bio-systems, Inc. (NASDAQ: ... offering of units of common stock and warrants at ... of $20 million, prior to deducting underwriting discounts and ... shares and warrants are immediately separable and will be ... to begin trading on The NASDAQ Stock Market under ...
(Date:8/21/2014)... Hermann Health System and The University of Texas ... to provide a new level of specialized breast screening at ... Houston area. Starting in ... professional breast radiology services for five of Memorial Hermann,s 10 ... Woodlands , Northeast, Southwest and Sugar Land ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
Autolensmeter with color 5.7 inch LCD screen and built in printer....
... CF-60UVi is a diversified wide-angle ... FAG, ICG (optional) with various ... in the market), 40 degrees ... one picture and 30 degrees ...
... to eliminate the subjective nature of manual ... repeatable, objective measurements every time. The easy ... operating system ensure fast and simple operation. ... lens positioning and, in auto mode, users ...
An ideal basic fundus fluorescein camera with quality enhancing features at a mid-range price point. The camera has 1.7x magnification at 60 degree and 2.5x at 40 degree....
Medicine Products: